Oxford Immunotec’s T-SPOT Discovery SARS-CoV-2 Test is Used in UK Com-COV Clinical Trial to Investigate the T Cell Response...
April 27 2021 - 9:15AM
Oxford Immunotec, a global, high-growth diagnostics company part of
PerkinElmer (NYSE: PKI), today announced that its
T-SPOT
® Discovery SARS-CoV-2 kit will be used for
T cell testing in the UK Com-COV trial. The company is
collaborating with the Oxford Vaccine Group, part of the team that
developed the Oxford-AstraZeneca vaccine, who is leading the
Com-COV trial. The trial will help understanding of the effects on
the immune response when different combinations of approved
COVID-19 vaccines are administered for the first and second
immunization doses. This study is funded by the UK Vaccine Task
Force and the National Institute for Health Research (NIHR).
The Com-COV trial aims to understand how well people’s immune
systems respond when they are primed with one type of vaccine, then
boosted with another and to see how effective the response is when
the second dose is separated from the first dose by different
periods of time. The study will also examine how common vaccine
reactions, such as fever, are after such “mixed” schedules. The
first stage of this program has already recruited 830 participants,
but has recently been expanded to include a second stage recruiting
an additional 1,050, aged over 50, who will have a complete
analysis of their immune response to vaccination carried out
(including T cells). Combining vaccines might give broader,
longer-lasting immunity against the virus and new variants of it.
The study will also give useful information about extending the gap
between prime and boost as well as a better understanding of
whether combining different vaccines creates a more flexible
immunization program, potentially allowing more people to be
immunized more quickly. The vaccines being examined in the study
are AstraZeneca ChadOx1 nCoV-19, Pfizer BioNTech BNT162b2, the
Moderna mRNA vaccine and the protein adjuvant vaccine produced by
Novavax.
The custom version of the Company’s T-SPOT Discovery SARS-CoV-2
kit (for research use only) will be used to assess if the
vaccination combinations induce a T cell response in study
subjects. The kit uses the T-SPOT technology platform, a
commercialized, standardized ELISPOT platform, which allows for the
reproducible measurement of T cells reactive to SARS-CoV-2. Testing
for an immune response using T cells may offer several advantages
over conventional antibody testing due to the limitations reported
with antibody testing. Of particular importance is that T cells
have been shown to be long lived, whereas antibodies can wane over
time. This could give an added importance to longer-term T cell
testing well after initial infection. The T-SPOT Discovery
SARS-CoV-2 test has also demonstrated in previous studies that a
high SARS-CoV-2 specific T cell response may be associated with
protection from infection.
Dr. Peter Wrighton-Smith, CEO of Oxford Immunotec said, “We are
proud to be partnering with the Oxford Vaccine Group on this
critical clinical trial. Measuring the T cell response in a
standardized way is vital for a complete understanding of the
immune response to vaccines and will help drive the understanding
of the most effective immunization program.”
For further information on the Com-COV trial visit:
www.comcovstudy.org.uk
For further information visit: www.tspotdiscovery.com
T-SPOT
Discovery SARS-CoV-2 is for research use
only, not for use in diagnostic procedures.
About Oxford ImmunotecOxford Immunotec is
a global, high-growth diagnostics company and part of the
PerkinElmer group. We bring energy and invention to a world in need
of diagnostic truth. We are uniquely placed as the only company in
the world offering regulated ELISPOT assays for T cell measurement,
with approval around the globe. Our leading product, the T-SPOT.TB
test, is used for diagnosing infection with Tuberculosis, the
world’s largest cause of death from infectious disease. The Company
is an experienced manufacturer of IVD tests, operating under a
fully audited Quality Management System, ensuring rigorous batch
control. The company has manufactured in excess of 20 million
clinical T cell tests for TB infection. The T-SPOT.TB test has been
approved for sale in over 50 countries, including the United States
(where it has received pre-market approval from the Food and Drug
Administration), Europe (where it has obtained a CE mark), as well
as Japan and China. The recently released T-SPOT.COVID test is CE
marked in Europe for clinical use to understand the T cell immune
response to SARS-CoV-2 infection and has been submitted to the FDA
for emergency use authorization in the US (www.tspotcovid.com). The
Company is headquartered near Oxford, U.K. and in Marlborough, MA.
Additional information can be found at www.oxfordimmunotec.com.
About the Oxford Vaccine GroupThe Oxford
Vaccine Group (OVG) conducts studies of new and improved vaccines
for children and adults and is based in the Department of
Pediatrics at the University of Oxford. The group is led by
Professor Andrew J Pollard. OVG was founded in 1994 by Professor E.
Richard Moxon. The multidisciplinary group, led by Professor
Pollard since 2001, includes consultants in vaccinology, a Director
of Clinical Trials, a Senior Clinical Trials Manager, adult and
pediatric clinical research fellows, adult and pediatric research
nurses, project managers, statisticians, QA manager, Clinical
Trials IT and Development Lead, and an administration team. Our
team also includes post-doctoral scientists, research assistants
and DPhil students and we work together with professionals from a
range of specialties such as immunologists, microbiologists,
epidemiologists, health communicators, and a sociologist, a
community pediatrician, the local Health Protection team and a
bioethicist. OVG is a UKCRC registered clinical trials unit working
in collaboration with the Primary Care Trials Unit at the
University (registration number: 52). For more information see:
http://www.ukcrc-ctu.org.uk/
About PerkinElmerPerkinElmer enables
scientists, researchers and clinicians to address their most
critical challenges across science and healthcare. With a mission
focused on innovating for a healthier world, we deliver unique
solutions to serve the diagnostics, life sciences, food and applied
markets. We strategically partner with customers to enable earlier
and more accurate insights supported by deep market knowledge and
technical expertise. Our dedicated team of about 14,000 employees
worldwide is passionate about helping customers work to create
healthier families, improve the quality of life, and sustain the
wellbeing and longevity of people globally. The Company reported
revenue of approximately $3.8 billion in 2020, serves customers in
190 countries, and is a component of the S&P 500 index.
Additional information is available through 1-877-PKI-NYSE, or at
www.perkinelmer.com.
For Media Inquiries:
US: Mary ConwayMKC Strategies, LLCTel: +1 (516)
606-6545 MConway@MKCStrategies.com
UK: Megan AndersonZPB AssociatesMobile:
07597572287Office: (020) 7018
1124megan.anderson@zpb-associates.com
PerkinElmer (NYSE:PKI)
Historical Stock Chart
From Apr 2024 to May 2024
PerkinElmer (NYSE:PKI)
Historical Stock Chart
From May 2023 to May 2024